Commentary 10.1172/JCI127927

c-Src is in the effector pathway linking uPAR and podocyte injury

Jeffrey B. Kopp and Jurgen Heymann

Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.

Address correspondence to: Jeffrey B. Kopp, 10 Center Dr., 3N116, NIH, Bethesda, Maryland 20892-1268, USA. Phone: 301.594.3403; Email: jbkopp@nih.gov.

Find articles by Kopp, J. in: JCI | PubMed | Google Scholar | Orcid 24x24

Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.

Address correspondence to: Jeffrey B. Kopp, 10 Center Dr., 3N116, NIH, Bethesda, Maryland 20892-1268, USA. Phone: 301.594.3403; Email: jbkopp@nih.gov.

Find articles by Heymann, J. in: JCI | PubMed | Google Scholar

First published April 2, 2019 - More info

Published in Volume 129, Issue 5 on May 1, 2019
J Clin Invest. 2019;129(5):1827–1829. https://doi.org/10.1172/JCI127927.
© 2019 American Society for Clinical Investigation
First published April 2, 2019 - Version history

The role of urokinase-type plasminogen activator receptor (uPAR) in kidney physiology and pathology has attracted considerable attention. The protein uPAR has dual functions: as a key regulator of plasmin generation and a component of the innate immune system. In the current issue, Wei and colleagues describe a transgenic mouse expressing Plaur RNA in glomerular podocytes. The mice manifested podocyte injury, including c-Src phosphorylation, proteinuria, and focal segmental glomerulosclerosis (FSGS). Plaur-transgenic mice on a β3 integrin–deficient background were protected from podocyte injury. Renal biopsies from subjects with FSGS, but not those with other glomerular diseases, manifested increased c-Src phosphorylation in podocytes. These findings suggest a novel injury mechanism in FSGS, with possible implications for new treatment strategies.

Preview pages

Reset
Page preview
1828 Page 1827 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Order Online
  • Print subscription
  • $795
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement